Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: A matched case-control study

The Lancet Respiratory Medicine

Volumn 4, Issue 5, 2016, Pages 399-406

  Moore, Matthew R ^a   Link Gelles, Ruth ^a   Schaffner, William ^b   Lynfield, Ruth ^c   Holtzman, Corinne ^c   Harrison, Lee H ^d   Zansky, Shelley M ^e   Rosen, Jennifer B ^f   Reingold, Arthur ^g,h   Scherzinger, Karen ⁱ   Thomas, Ann ^j   Guevara, Ramon E ^k   Motala, Tasneem ^k   Eason, Jeffrey ^l   Barnes, Meghan ^m   Petit, Susan ⁿ   Farley, Monica M ^o,p   McGee, Lesley ^a   Jorgensen, James H ^q   Whitney, Cynthia G ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MINNESOTA DEPARTMENT OF HEALTH   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e NEW YORK STATE DEPARTMENT OF HEALTH   (United States)

^f NEW YORK CITY DEPARTMENT OF HEALTH AND MENTAL HYGIENE   (United States)

^g CALIFORNIA EMERGING INFECTIONS PROGRAM   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ UNIVERSITY OF NEW MEXICO   (United States)

^j OREGON PUBLIC HEALTH DIVISION   (United States)

^k Los Angeles County Department of Public Health   (United States)

^l UTAH DEPARTMENT OF HEALTH   (United States)

^m Colorado Department of Public Health and Environment ^*  (United States)

ⁿ CDC   (United States)

^o EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^p ATLANTA VA MEDICAL CENTER   (United States)

^q Mays Cancer Center at UT Health San Antonio   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CEFOTAXIME; CEFTRIAXONE; CHLORAMPHENICOL; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; LEVOFLOXACIN; PENICILLIN DERIVATIVE; PNEUMOCOCCUS VACCINE; TETRACYCLINE; VANCOMYCIN; 13-VALENT PNEUMOCOCCAL VACCINE;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; CASE CONTROL STUDY; CHILD; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PNEUMOCOCCAL INFECTION; PNEUMOCOCCAL MENINGITIS; PRESCHOOL CHILD; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIA; UNITED STATES; INFANT; MASS IMMUNIZATION; PROCEDURES; REGISTER; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

CASE-CONTROL STUDIES; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; MALE; MASS VACCINATION; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; REGISTRIES; TREATMENT OUTCOME; UNITED STATES;

EID: 84960901678     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(16)00052-7     Document Type: Article

References (27)

1. Preventing pneumococcal disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000, 49(RR-9):1-35. Centers for Disease Control and Prevention.
2. Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010, 201:32-41.
3. Smith PJ, Nuorti JP, Singleton JA, Zhao Z, Wolter KM Effect of vaccine shortages on timeliness of pneumococcal conjugate vaccination: results from the 2001-2005 National Immunization Survey. Pediatrics 2007, 120:e1165-e1173.
4. Moore MR, Gertz RE, Woodbury RL, et al. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J Infect Dis 2008, 197:1016-1027.
5. Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010, 201:32-41.
6. Prevnar 13: clinical review of new product license application US Food and Drug Administration, (accessed Feb 22, 2016). http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm201667.htm.
7. Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children-Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep 2010, 59:258-261. Centers for Disease Control and Prevention.
8. Moore MR Evaluating the effectiveness of a 13-valent pneumococcal conjugate vaccine among children (accessed Dec 3, 2012). http://www.thelancet.com/protocol-reviews/09PRT-8166.
9. Prevention of pneumococcal disease among infants and children. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010, 59(RR-11):1-19. Centers for Disease Control and Prevention.
10. ABCs report: Streptococcus pneumoniae Centers for Disease Control and Prevention, (accessed Feb 22, 2016). http://www.cdc.gov/abcs/reports-findings/surv-reports.html.
11. 2010 bridged-race population estimates, United States July 1st resident population United States Department of Health and Human Services, Centers for Disease Control and PreventionCenters for Disease Control and Prevention, National Center for Health StatisticsNational Center for Health Statistics, (accessed June 5, 2015). http://wonder.cdc.gov/bridged-race-v2013.html.
12. Park IH, Moore MR, Treanor JJ, et al. Differential effects of pneumococcal vaccines against serotypes 6A and 6C. J Infect Dis 2008, 198:1818-1822.
13. Moore MR, Link-Gelles R, Schaffner W, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis 2015, 15:301-309.
14. M100-S24-performance standards for antimicrobial susceptibility testing; twenty-fourth informational supplement 2014, Clinical and Laboratory Standards Institute, Clinical and Laboratory Standards Institute, Wayne, PA.
15. Dupont WD Power calculations for matched case-control studies. Biometrics 1988, 44:1157-1168.
16. Ury HK Efficiency of case-control studies with multiple controls per case: continuous or dichotomous data. Biometrics 1975, 31:643-649.
17. Whitney CG, Pilishvili T, Farley MM, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 2006, 368:1495-1502.
18. Clearance of information products disseminated outside CDC for public use Centers for Disease Control and Prevention, Office of the DirectorOffice of the Director, (accessed Jan 11, 2016). http://www.cdc.gov/maso/Policy/PublicUse.pdf.
19. Khoie T Clinical review of biologics license application for Prevnar 13 (pneumococcal 13-valent conjugate vaccine (diphtheria CRM197 protein)) 2010, US Food and Drug Administration, Silver Spring, MD.
20. Andrews NJ, Waight PA, Burbidge P, et al. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. Lancet Infect Dis 2014, 14:839-846.
21. Waight PA, Andrews NJ, Ladhani NJ, Sheppard CL, Slack MP, Miller E Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis 2015, 15:535-543.
22. National strategy for combatting antibiotic resistant bacteria The White House, (accessed Feb 22, 2016). https://www.whitehouse.gov/sites/default/files/docs/carb_national_strategy.pdf.
23. Moore MR, Hyde TB, Hennessy TW, et al. Impact of a conjugate vaccine on community-wide carriage of nonsusceptible Streptococcus pneumoniae in Alaska. J Infect Dis 2004, 190:2031-2038.
24. Nuorti JP, Whitney CG Prevention of pneumococcal disease among infants and children-use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine-recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010, 59(RR-11):1-18.
25. Blumberg SJ, Ganesh N, Luke JV, Gonzales G Wireless substitution: state-level estimates from the National Health Interview Survey, 2012. Natl Health Stat Report 2013, 70:1-16.
26. Krieger N, Chen JT, Waterman PD, Soobader MJ, Subramanian SV, Carson R Choosing area based socioeconomic measures to monitor social inequalities in low birth weight and childhood lead poisoning: The Public Health Disparities Geocoding Project (US). J Epidemiol Commun Health 2003, 57:186-199.
27. De Serres G, Pilishvili T, Link-Gelles R, et al. Use of surveillance data to estimate the effectiveness of the 7-valent conjugate pneumococcal vaccine in children less than 5 years of age over a 9 year period. Vaccine 2012, 30:4067-4072.